AstraZeneca plans $1.5 billion ADCs manufacturing facility in Singapore
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
The USFDA has issued 5 observations pursuant to the completion of audit
The demand in Africa for COVID-19 vaccines has declined
Executes the first project for developing and manufacturing a novel anticancer mAb
The plan is to set up an ultramodern Solvent Recovery Plant for third party purposes
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
The unit’s contribution to the company's revenue US$3.85 million in the last fiscal year
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
Subscribe To Our Newsletter & Stay Updated